Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551753 | 0.76 | PIK3CD (0.63) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL9509104 | 0.76 | PIK3CD (0.58) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL8282177 | 0.72 | PIK3CD (1.00) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL23518166 | 0.70 | PIK3CD (0.65) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL23518055 | 0.70 | PIK3CD (0.65) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL12058789 | 0.69 | PIK3CD (0.69) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL21009688 | 0.68 | PIK3CD (0.61) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL21009380 | 0.68 | PIK3CD (0.61) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL15354755 | 0.68 | PIK3CD (0.72) | PIK3CDGRIN1GRIN2BCHRNA7 | |
| SCHEMBL15354726 | 0.68 | PIK3CD (0.72) | PIK3CDGRIN1GRIN2BCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | HONGYI & ASS LLC (US) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048893-A1 | Compounds for Treating Neurodegenerative Diseases and Cancers | SNCA, NGF, SLC18A2 | PIK3CD 3712/4885GRIN1 505/4885GRIN2B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.